Market Overview

Rosetta Genomics Gets Patent Allowance For microRNA-based Ovarian Cancer Treatment

Share:

Rosetta Genomics Ltd. (NASDAQ: ROSG) revealed that the Patent and Trademark Office in the United States has issued a notice of allowance for its patent, entitled "Compositions and methods for treatment of Ovarian Cancer." According to the company, it covered a method of treatment for ovarian cancer by administering an inhibitor of miR-27a.

Aside from that, Rosetta said the Israel Patent Office has also allowed its Application entitled "Compositions and Methods for Modulating Cell Proliferation and Cell Death," to claim use of miR-34a or its variants for treating p53-negative cancers. The company indicated that this application covered a core element of its microRNA technology in the development of cancer therapeutics in connection with p53-negative cancers. That included lymphoma, breast cancer, ovarian cancer, liver cancer, skin cancer, certain types of lung cancer, and others.

The company stated the patent was jointly owned with Yeda R&D Co. Ltd., the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel. The company added that the technology was licensed to Mirna Therapeutics.

Rosetta president and CEO, Kenneth Berlin, said, "These patent grants further strengthen our international intellectual property position and complement already granted patents. Our growing patent estate continues to be a valuable asset for Rosetta as it provides protection for our core product portfolio, supports our research and development efforts and offers multiple opportunities to monetize patents outside our core diagnostics platforms."

He continued, "We believe the new U.S. patent may be of great value in the development of new treatment options for platinum-resistant ovarian cancer patients. Our goal is to monetize this U.S. patent and the related technology through a potential partnership."

The stock traded 9 percent higher on Monday.

 

Related Articles (ROSG)

View Comments and Join the Discussion!

Posted-In: Biotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com